Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma

被引:22
作者
Collins, Graham P. [1 ]
Parker, Anne N. [2 ]
Pocock, Christopher [3 ]
Kayani, Irfan [4 ]
Sureda, Anna [5 ]
Illidge, Tim [6 ]
Ardeshna, Kirit [7 ]
Linch, David C. [7 ,8 ]
Peggs, Karl S. [7 ,8 ]
机构
[1] Churchill Hosp, Oxford Canc & Haematol Ctr, Dept Haematol, Oxford OX3 7LJ, England
[2] Beatson West Scotland Canc Ctr, HPC Transplant Programme, Glasgow, Lanark, Scotland
[3] East Kent Hosp NHS Trust, Dept Haematol, Canterbury, Kent, England
[4] Univ Coll London Hosp NHS Trust, Dept Nucl Med, London, England
[5] Univ Cambridge, Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England
[6] Univ Manchester, Christie Hosp, Inst Canc Sci, Manchester, Lancs, England
[7] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England
[8] UCL, Inst Canc, Dept Haematol, London WC1E 6BT, England
关键词
Hodgkin lymphoma; relapse; chemotherapy; transplantation; STEM-CELL-TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; INVOLVED FIELD RADIOTHERAPY; BLOOD PROGENITOR-CELL; SALVAGE THERAPY; BRENTUXIMAB VEDOTIN; PROGNOSTIC-FACTORS; MINI-BEAM; RADIATION-THERAPY;
D O I
10.1111/bjh.12582
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:39 / 52
页数:14
相关论文
共 89 条
[1]   Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].
Anderlini, Paolo ;
Saliba, Rima ;
Acholonu, Sandra ;
Giralt, Sergio A. ;
Andersson, Borje ;
Ueno, Naoto T. ;
Hosing, Chitra ;
Khouri, Issa F. ;
Couriel, Daniel ;
de Lima, Marcos ;
Qazilbash, Muzaffar H. ;
Pro, Barbara ;
Romaguera, Jorge ;
Fayad, Luis ;
Hagemeister, Frederick ;
Younes, Anas ;
Munsell, Mark F. ;
Champlin, Richard E. .
HAEMATOLOGICA, 2008, 93 (02) :257-264
[2]   ESHAP is an active regimen for relapsing Hodgkin's disease [J].
Aparicio, J ;
Segura, A ;
Garcerá, S ;
Oltra, A ;
Santaballa, A ;
Yuste, A ;
Pastor, M .
ANNALS OF ONCOLOGY, 1999, 10 (05) :593-595
[3]   Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group [J].
Baetz, T ;
Belch, A ;
Couban, S ;
Imrie, K ;
Yau, J ;
Myers, R ;
Ding, K ;
Paul, N ;
Shepherd, L ;
Iglesias, J ;
Meyer, R ;
Crump, M .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1762-1767
[4]   Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 [J].
Bartlett, N. L. ;
Niedzwiecki, D. ;
Johnson, J. L. ;
Friedberg, J. W. ;
Johnson, K. B. ;
van Besien, K. ;
Zelenetz, A. D. ;
Cheson, B. D. ;
Canellos, G. P. .
ANNALS OF ONCOLOGY, 2007, 18 (06) :1071-1079
[5]   Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma [J].
Benekli, M. ;
Smiley, S. L. ;
Younis, T. ;
Czuczman, M. S. ;
Hernandez-Ilizaliturri, F. ;
Bambach, B. ;
Battiwalla, M. ;
Padmanabhan, S. ;
McCarthy, P. L., Jr. ;
Hahn, T. .
BONE MARROW TRANSPLANTATION, 2008, 41 (07) :613-619
[6]   Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma [J].
Biswas, Tithi ;
Culakova, Eva ;
Friedberg, Jonathan W. ;
Kelly, Jennifer L. ;
Dhakal, Sughosh ;
Liesveld, Jane ;
Phillips, Gordon L. ;
Constine, Louis S. .
RADIOTHERAPY AND ONCOLOGY, 2012, 103 (03) :367-372
[7]   Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD [J].
Bonfante, V ;
Santoro, A ;
Viviani, S ;
Devizzi, L ;
Balzarotti, M ;
Soncini, F ;
Zanini, M ;
Valagussa, P ;
Bonadonna, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :528-534
[8]   Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry [J].
Brice, P ;
Bouabdallah, R ;
Moreau, P ;
Divine, M ;
Andre, M ;
Aoudjane, M ;
Fleury, J ;
Anglaret, B ;
Baruchel, A ;
Sensebe, L ;
Colombat, P .
BONE MARROW TRANSPLANTATION, 1997, 20 (01) :21-26
[9]   Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma [J].
Chau, I ;
Harries, M ;
Cunningham, D ;
Hill, M ;
Ross, PJ ;
Archer, CD ;
Norman, AR ;
Wotherspoon, A ;
Koh, DM ;
Gill, K ;
Uzzell, M ;
Prior, Y ;
Catovsky, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) :970-977
[10]   Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma [J].
Chen, Robert ;
Palmer, Joycelynne M. ;
Thomas, Sandra H. ;
Tsai, Ni-Chun ;
Farol, Len ;
Nademanee, Auayporn ;
Forman, Stephen J. ;
Gopal, Ajay K. .
BLOOD, 2012, 119 (26) :6379-6381